Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 158


Analysis of the genes coding for the BRCA1-interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases.

Novak DJ, Sabbaghian N, Maillet P, Chappuis PO, Foulkes WD, Tischkowitz M.

Breast Cancer Res Treat. 2009 Sep;117(2):453-9. doi: 10.1007/s10549-008-0134-y. Epub 2008 Aug 10.


Germline RAP80 mutations and susceptibility to breast cancer.

Akbari MR, Ghadirian P, Robidoux A, Foumani M, Sun Y, Royer R, Zandvakili I, Lynch H, Narod SA.

Breast Cancer Res Treat. 2009 Jan;113(2):377-81. doi: 10.1007/s10549-008-9938-z. Epub 2008 Feb 28.


Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility.

Osorio A, Barroso A, García MJ, Martínez-Delgado B, Urioste M, Benítez J.

Breast Cancer Res Treat. 2009 Jan;113(2):371-6. doi: 10.1007/s10549-008-9933-4. Epub 2008 Feb 13.


Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.

Distelman-Menachem T, Shapira T, Laitman Y, Kaufman B, Barak F, Tavtigian S, Friedman E.

Fam Cancer. 2009;8(2):127-33. doi: 10.1007/s10689-008-9216-6. Epub 2008 Sep 17.


Breast cancer risk and the BRCA1 interacting protein CTIP.

Gorringe KL, Choong DY, Lindeman GJ, Visvader JE, Campbell IG.

Breast Cancer Res Treat. 2008 Nov;112(2):351-2. Epub 2007 Dec 20.


Molecular and in silico analysis of BRCA1 and BRCA2 variants.

Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, Digennaro M, Schittulli F, Lacalamita R, Paradiso A.

Mutat Res. 2008 Sep 26;644(1-2):64-70. doi: 10.1016/j.mrfmmm.2008.07.005. Epub 2008 Jul 18.


Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.

Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2009 May;115(1):51-5. doi: 10.1007/s10549-008-0052-z. Epub 2008 May 16.


Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.

Lewis AG, Flanagan J, Marsh A, Pupo GM, Mann G, Spurdle AB, Lindeman GJ, Visvader JE, Brown MA, Chenevix-Trench G; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.

Breast Cancer Res. 2005;7(6):R1005-16. Epub 2005 Oct 21.


A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.

Freedman ML, Penney KL, Stram DO, Riley S, McKean-Cowdin R, Le Marchand L, Altshuler D, Haiman CA.

Cancer Res. 2005 Aug 15;65(16):7516-22.


Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage.

Wang B, Elledge SJ.

Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20759-63. Epub 2007 Dec 5.


Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Cypriot family.

Hadjisavvas A, Adamou A, O'Dowd Phanis C, Todd CM, Kitsios P, Kyriacou K, Christodoulou CG.

Oncol Rep. 2002 Mar-Apr;9(2):383-6.


Mutation screening of the MERIT40 gene encoding a novel BRCA1 and RAP80 interacting protein in breast cancer families.

Solyom S, Patterson-Fortin J, Pylkäs K, Greenberg RA, Winqvist R.

Breast Cancer Res Treat. 2010 Feb;120(1):165-8. doi: 10.1007/s10549-009-0453-7. Epub 2009 Jul 2.


Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.

Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, Coene I, Pavlu H, Kosinova V, Kuklova J, Claes K.

BMC Cancer. 2008 May 20;8:140. doi: 10.1186/1471-2407-8-140.


Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.

García MJ, Fernández V, Osorio A, Barroso A, Fernández F, Urioste M, Benítez J.

Carcinogenesis. 2009 Nov;30(11):1898-902. doi: 10.1093/carcin/bgp218. Epub 2009 Sep 8.


The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.

Palma MD, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Tigges-Cardwell J, Mason BA, Rebbeck TR, Nathanson KL.

Cancer Res. 2008 Sep 1;68(17):7006-14. doi: 10.1158/0008-5472.CAN-08-0599. Epub 2008 Aug 14.


BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.

Eachkoti R, Hussain I, Afroze D, Aejazaziz S, Jan M, Shah ZA, Das BC, Siddiqi MA.

Cancer Lett. 2007 Apr 18;248(2):308-20. Epub 2006 Sep 22.


Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.

Guénard F, Labrie Y, Ouellette G, Beauparlant CJ, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M, Durocher F; INHERIT BRCAs.

Fam Cancer. 2007;6(4):483-90. Epub 2007 Jul 17.


Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients.

Vidal-Millán S, Taja-Chayeb L, Gutiérrez-Hernández O, Ramírez Ugalde MT, Robles-Vidal C, Bargallo-Rocha E, Mohar-Betancourt A, Dueñas-González A.

Eur J Gynaecol Oncol. 2009;30(5):527-30.


Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer.

Desjardins S, Beauparlant JC, Labrie Y, Ouellette G, Durocher F; INHERIT BRCAs.

BMC Cancer. 2009 Jun 12;9:181. doi: 10.1186/1471-2407-9-181.


Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene.

Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, Mistrik M, Aittomäki K, Blomqvist C, Heikkilä P, Lukas J, Nevanlinna H, Bartek J.

Mol Oncol. 2008 Dec;2(4):296-316. doi: 10.1016/j.molonc.2008.09.007. Epub 2008 Oct 7.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk